Meissner has announced the expansion of its TepoFlex® biocontainer platform into freeze and thaw applications, enabling biopharmaceutical manufacturers to apply a trusted container solution to low-temperature processing environments.
The TepoFlex® polyethylene film platform has a long-standing reputation for durability and performance, built over nearly two decades of implementation. By leveraging these proven material properties, the biocontainers are designed to deliver consistent reliability throughout harsh freeze and thaw conditions, enhancing their value for storage, transport and process integration of drug substances and drug products.
The 2D TepoFlex® biocontainers are suitable for freezing down to -80°C and are offered as single-use solutions across multiple volumes, ranging from 50 mL to 10 L. This breadth of sizing allows manufacturers to select containers that align precisely with their process scale and operational requirements.
Designed for ease of integration, the flexible single-use biocontainers can be incorporated into existing freeze and thaw infrastructure with minimal disruption. Compatibility with both blast freezers and vertical plate freezers ensures flexibility across different facility layouts and manufacturing stages.
The expanded TepoFlex® offering provides a robust single-use option for biopharmaceutical manufacturers looking to protect sensitive products under demanding freeze and thaw conditions while maintaining operational flexibility.
Manufacturing takes place in ISO-certified cleanrooms using qualified components to ensure biocompatibility and regulatory alignment. Meissner’s Applications Engineering Team works closely with customers to support system design and optimisation, ensuring assemblies are configured to meet specific application requirements.
Drawing on four decades of technical expertise, Meissner focuses on delivering a high-quality customer experience by understanding client needs and partnering closely to support long-term operational success.
To discover why leading biopharmaceutical manufacturers trust TepoFlex® for their most essential freeze and thaw applications, visit Meissner’s website at https://www.meissner.com/tepoflex-freeze-thaw where technical resources are available for download.
Additionally, visiting https://www.meissner.com/applications/freeze-thaw/ provides an overview of all of Meissner’s single-use freeze and thaw platform offerings.
About Meissner
Meissner manufactures advanced microfiltration products and therapeutic manufacturing systems for critical pharmaceutical and biopharmaceutical applications, such as sterilization of injectable drugs, and the development and manufacture of life-enhancing/life-saving drugs, therapeutics, biologics, and cell and gene therapies.
Meissner’s manufacturing campuses include a headquarters location in Camarillo, California, USA, a European manufacturing location in Castlebar, Ireland, and buildout of a $250 million facility in Athens, Georgia.
Meissner’s product portfolios are built upon a solid foundation of quality, operational excellence, and technical expertise for delivery of high-performance products that support clients’ critical applications. For more information about Meissner, please visit https://www.meissner.com.
